- Politics
- Diversity, equity and inclusion
- Financial Decision Making
- Telehealth
- Patient Experience
- Leadership
- Point of Care Tools
- Product Solutions
- Management
- Technology
- Healthcare Transformation
- Data + Technology
- Safer Hospitals
- Business
- Providers in Practice
- Mergers and Acquisitions
- AI & Data Analytics
- Cybersecurity
- Interoperability & EHRs
- Medical Devices
- Pop Health Tech
- Precision Medicine
- Virtual Care
- Health equity
Wellington Management Closes $393M Biomedical Innovation Fund
The firm will invest in biotech companies focused on drug discovery and development.
Wellington Management today announced the close of a $393 million Biomedical Innovation Fund I to invest in private biotechnology companies focused on drug discovery and development.
The close of the fund expands Wellington’s private investment platform which totals $2.7 billion. The new funding will be used to help the companies advance their scientific program.
“Biotechnology represents an exciting investment area, driven by an explosion in fundamental biomedical knowledge and a growing ability to deploy that knowledge in the service of breakthrough drug discovery,” said Bob Deresiewicz, M.D., senior managing director at Wellington, an independent investment management firm.
Wellington leverages its biomedical, scientific and industry knowledge to identify assets that could advance medical practice, Deresiewicz said.
Inside Digital Health™ reached out to Wellington Management to learn more about the close the fund but could not get a hold of anyone.
This is not the firm’s first healthcare investment either. Back in July, Wellington Management led a $73 million Series D funding round for Omada Health, a company that uses health coaching, connected devices, peer support and digital interventions to help patients manage chronic conditions and behavioral health.
Wellington’s $393 million fund adds to the more than $200 million raised by Ajax Health earlier this year to accelerate med-tech innovations.
The fund also follows the National Institutes of Health announcement from the beginning of October that it awarded $20 million to five research institutions to accelerate the development of biomedical health technology and improve patient care.
As 2019 comes to a close, funding in health-tech is shaping up to end the year like it opened — with more investments in the space.
Get the best insights in digital health directly to your inbox.
Related
Avidity Biosciences Earns $100M for Precision Medicine Platform
Novartis and Microsoft Partner to Transform Medicine with AI
PercayAI and Canopy Biosciences Partner to Improve Drug Research and Development
Waiting for FDA to Catch Up: What Hospitals Can Do to Address Supply Chain and Device Shortages
July 6th 2021Peter Urbanowicz, managing director and co-head of Alvarez and Marsal’s Healthcare Industry Group, discusses the FDA’s new focus in addressing supply chain and device shortages posed by the COVID-19 pandemic and what hospitals should be doing in the meantime to adjust.
